reglab/statecodes huggingface dataset:
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1868 - Tiletamine or Zolazepam or Both

Current through Register Vol. 48, No. 28, July 12, 2024
Tiletamine or zolazepam or both, or any salt of either of
				  them. Some trade or other names for a tiletamine-zolazepam combination product:
				  Telazol. Some trade or other names for tiletamine:
				  2-(ethylamino)-2-(2-thienyl)- cyclohexanone. Some trade or other names for
				  zolazepam: 4-(2-fluorophenyl)- 6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e],
				  [1,4]-diazepin-7(1H)-one, and flupyrazapon.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1870 - Pentazocine and Aspirin Compound

Current through Register Vol. 48, No. 28, July 12, 2024
Any material, compound, mixture or preparation containing not
				  more than 12.5 milligrams of pentazocine or any of its salts, per 325
				  milligrams of aspirin.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1875 - Pentazocine and Acetaminophine

Current through Register Vol. 48, No. 28, July 12, 2024
Any material, compound, mixture or preparation containing not
				  more than 25 milligrams of Pentazocine or any of its salts, per 650 milligrams
				  of Acetaminophen.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1880 - Pentazocine and Naloxone

Current through Register Vol. 48, No. 28, July 12, 2024
Pentazocine and Naloxone
Any material, compound, mixture or preparation containing not
				  more than 50 milligrams of pentazocine or any of its salts plus naloxone HCl
				  USP 0.5 milligrams, per dosage unit.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1900 - Narcotic Drugs

Current through Register Vol. 48, No. 28, July 12, 2024
Unless specifically excepted or unless listed in another
				  schedule, any material, compound, mixture, or preparation containing limited
				  quantities of any of the narcotic drugs listed in Sections
				  2070.1905 to
				  2070.1940, or their
				  salts calculated as the free anhydrous base or alkaloid.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1905 - Codeine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than
				  1.8
				  grams of codeine, or any of its salts, per 100 milliliters or not more than 90
				  milligrams per dosage unit, with an equal or greater quantity of an
				  isoquinoline alkaloid of opium.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1910 - Codeine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than
				  1.8
				  grams of codeine, or any of its salts, per 100 milliliters or not more than 90
				  milligrams per dosage unit, with one or more active non-narcotic ingredients in
				  recognized therapeutic amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1915 - Dihydrocodeinone

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 300 milligrams of dihydrocodeinone, or any of
				  its salts, per 100 milliliters or not more than 15 milligrams per dosage unit,
				  with a fourfold or greater quantity of an isoquinoline alkaloid of
				  opium.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1920 - Dihydrocodeinone

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 300 milligrams of dihydrocodeinone, or any of
				  its salts, per 100 milliliters or not more than 15 milligrams per dosage unit,
				  with one or more active, non-narcotic ingredients in recognized therapeutic
				  amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1925 - Dihydrocodeine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than
				  1.8
				  grams of dihydrocodeine, or any of its salts per 100 milliliters or not more
				  than 90 milligrams per dosage unit, with one or more active, non-narcotic
				  ingredients in recognized therapeutic amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1930 - Ethylmorphine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 300 milligrams of ethylmorphine or any of its
				  salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with
				  one or more active, non-narcotic ingredients in recognized therapeutic
				  amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1935 - Opium

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 500 milligrams of opium per 100 milliliters or
				  per 100 grams, or not more than 25 milligrams per dosage unit, with one or more
				  active, non-narcotic ingredients in recognized therapeutic
				  amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1940 - Morphine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 50 milligrams of morphine, or any of its salts,
				  per 100 milliliters or per 100 grams with one or more active, non-narcotic
				  ingredients in recognized therapeutic amounts.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1960 - Anabolic Steroids

Current through Register Vol. 48, No. 28, July 12, 2024
Anabolic steroids, except the following anabolic steroids
				  listed in Sections
				  2070.1962 to
				  2070.1992
				  that are exempt.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1988 - Testosterone Cyp-50-Estradiol Cyp 2

Current through Register Vol. 48, No. 28, July 12, 2024
Testrosterone Cyp-50-Estradiol Cyp 2
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1990 - Testosterone Cypionate-Estradiol Cypionate Injection

Current through Register Vol. 48, No. 28, July 12, 2024
Testosterone Cypionate-Estradiol Cypionate
				  injection
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1992 - Testosterone Enanthate-Estradiol Valerate Injection

Current through Register Vol. 48, No. 28, July 12, 2024
Testosterone Enanthate-Estradiol Valerate
				  injection
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.1995 - Dronabinol (capsules)

Current through Register Vol. 48, No. 28, July 12, 2024
Dronabinol (synthetic) in sesame oil and encapsulated in a
				  soft gelation capsule in a U.S. Food and Drug Administration-approved drug
				  product. Some other names: (6aR-trans)-6a,7,8,10a_tetrahydro-6,6,9-
				  trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-o1; (-)-delta-9(trans)-
				  tetrahydrocannabinol.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart D - SCHEDULE OF CONTROLLED SUBSTANCES-SCHEDULE III › Section 2070.2000 - Excepted Compounds

Current through Register Vol. 48, No. 28, July 12, 2024
The Department may except by rule any compound, mixture, or
				  preparation containing any stimulant or depressant substance listed in Sections
				  2070.1610 and
				  2070.1700 from
				  the application of all or any part of this Act if the compound, mixture, or
				  preparation contains one or more active medicinal ingredients not having a
				  stimulant or depressant effect on the central nervous system, and if the
				  admixtures are included therein in combinations, quantity, proportion, or
				  concentration that vitiate the potential for abuse of the substances which have
				  a stimulant or depressant effect on the central nervous
				  system.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2100 - Schedule IV - Criteria

Current through Register Vol. 48, No. 28, July 12, 2024
The Department finds that the substances enumerated in
				  Schedule IV following meet the criteria established in Section 209 of the
				  Act.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2105 - Schedule IV - Enumeration

Current through Register Vol. 48, No. 28, July 12, 2024
The controlled substances listed in these Sections
				  2070.2110 through
				  2070.2600 are
				  included in Schedule IV.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2110 - Narcotic Drugs

Current through Register Vol. 48, No. 28, July 12, 2024
Unless specifically excepted or unless listed in another
				  schedule, any material, compound, mixture, or preparation containing limited
				  quantities of any of the following narcotic drugs listed in Sections
				  2070.2115
				  and
				  2070.2120, or
				  their salts calculated as the free anhydrous base or
				  alkaloid.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2115 - Difenoxin and Atropine Sulfate

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 1 milligram of difenoxin (DEA Drug Code No.
				  9618) and not less than 25 micrograms of atropine sulfate per dosage
				  unit.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2120 - Dextropropoxyphine

Current through Register Vol. 48, No. 28, July 12, 2024
Dextropropoxyphene
				  (Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2200 - Depressants

Current through Register Vol. 48, No. 28, July 12, 2024
Unless specifically excepted or unless listed in another
				  schedule, any material, compound, mixture, or preparation which contains any
				  quantity of the substances listed in Sections
				  2070.2210 to
				  2070.2325 having a
				  potential for abuse associated with a depressant effect on the central nervous
				  system.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2246 - Eluxadoline

Current through Register Vol. 48, No. 28, July 12, 2024
Eluxadoline
				  5-[[[(
2S
)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(
1S
)-1-(4-phenyl-1
H
-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
				  acid
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2400 - Fenfluramine

Current through Register Vol. 48, No. 28, July 12, 2024
Any material, compound, mixture, or preparation which
				  contains any quantity of the following substances, including its salts, isomers
				  (whether optical, position, or geometric), and salts of such isomers, whenever
				  the existence of such salts, isomers and salts of isomers is possible:
				  Fenfluramine
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2500 - Stimulants

Current through Register Vol. 48, No. 28, July 12, 2024
Unless specifically excepted or unless listed in another
				  schedule any material, compound, mixture, or preparation which contains any
				  quantity of the substances listed in Sections
				  2070.1605
				  to 2070.2580 having a stimulant
				  effect on the central nervous system, including its salts, isomers (whether
				  optical, position, or geometric), and salts of such isomers whenever the
				  existence of such salts, isomers, and salts of isomers is possible within the
				  specific chemical designation.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2580 - SPA

Current through Register Vol. 48, No. 28, July 12, 2024
SPA ((-)-1-dimethylamino-1,
				  2-diphenylethane).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2600 - Excepted Compounds

Current through Register Vol. 48, No. 28, July 12, 2024
The Department may except by rule any compound, mixture, or
				  preparation containing any depressant substance listed in Section
				  2070.2110 from the
				  application of all or any part of this Act if the compound, mixture, or
				  preparation contains one or more active medicinal ingredients not having a
				  depressant effect on the central nervous system, and if the admixtures are
				  included therein in combinations, quantity, proportion, or concentration that
				  vitiate the potential for abuse of the substances which have a depressant
				  effect on the central nervous system.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2650 - Stimulants

Current through Register Vol. 48, No. 28, July 12, 2024
Any material, compound, mixture, or preparation that contains
				  any quantity of the following substance listed in Section
				  2070.2655 having a
				  stimulant effect on the central nervous system, including its salts,
				  enantiomers (optical isomers) and salts of enantiomers (optical
				  isomers).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart E - SCHEDULE OF CONTROLLED SUBSTANCES - SCHEDULE IV › Section 2070.2655 - Ephedrine

Current through Register Vol. 48, No. 28, July 12, 2024
Ephedrine as the only active medicinal ingredient or in
				  combination with therapeutically insignificant quantities of another active
				  medicinal ingredient. Anything less than 200 milligrams of Guaifenesin shall be
				  considered therapeutically insignificant.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2700 - Schedule V - Criteria

Current through Register Vol. 48, No. 28, July 12, 2024
The Department finds that the substances enumerated in
				  Schedule V following meet the criteria established in Section 211 of the
				  Act.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2705 - Schedule V - Enumeration

Current through Register Vol. 48, No. 28, July 12, 2024
The controlled substances listed in these Sections
				  2070.2710 to
				  2070.2800 are
				  included in Schedule V.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2710 - Narcotic Drugs

Current through Register Vol. 48, No. 28, July 12, 2024
Any compound, mixture, or preparation containing limited
				  quantities of any of the following narcotic drugs listed in Sections
				  2070.2715 to
				  2070.2740, or their
				  salts calculated as the free anhydrous base or alkaloid, which also contains
				  one or more non-narcotic active medicinal ingredients in sufficient proportion
				  to confer upon the compound, mixture or preparation, valuable medicinal
				  qualities other than those possessed by the narcotic drug
				  alone.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2715 - Codeine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 200 milligrams of codeine, or any of its salts,
				  per 100 milliliters or per 100 grams.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2720 - Dihydrocodeine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 100 milligrams of dihydrocodeine; or any of its
				  salts, per 100 milliliters or per 100 grams.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2723 - Methylfentanyl

Current through Register Vol. 48, No. 28, July 12, 2024
3-Methylfentanyl
				  (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2725 - Ethylmorphine

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 100 milligrams of ethylmorphine; or any of its
				  salts, per 100 milliliters or per 100 grams.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2730 - Diphenoxylate

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 2.5 milligrams of diphenoxylate and not less
				  than 25 micrograms of atropine sulfate per dosage unit.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2735 - Opium

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 100 milligrams of opium per 100 milliliters or
				  per 100 grams.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2740 - Difenoxin

Current through Register Vol. 48, No. 28, July 12, 2024
Not more than 0.5 milligram of difenoxin (DEA Drug Code No.
				  9618) and not less than 25 micrograms of atropine sulfate per dosage
				  unit.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2070 - SCHEDULE OF CONTROLLED SUBSTANCES › Subpart F - SCHEDULE OF CONTROLLED SUBSTANCES- SCHEDULE V › Section 2070.2800 - Other Substances

Current through Register Vol. 48, No. 28, July 12, 2024
Any compound, mixture, or preparation which contains any
				  quantity of any controlled substance when such compound, mixture, or
				  preparation is not otherwise controlled in Schedules I, II, III, or
				  IV.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2075 - RESEARCH › Section 2075.10 - Confidentiality of research subjects

Current through Register Vol. 48, No. 28, July 12, 2024
Authority: The provisions of this Part issued under Sec. 508(b)
				of the Illinois Controlled Substances Act [720 ILCS
				570/508(b) ].
a) Any person authorized to conduct research
			 in controlled substances under the Illinois Controlled Substances Act [720 ILCS
			 570 ], who intends to maintain the confidentiality of those persons who are the
			 subjects of such research, shall upon authorization, or within a reasonable
			 time thereafter, submit to the Secretary of the Department of Human Services, a
			 separate request for each research project involving controlled substances,
			 which shall contain the following:
1) The
			 researcher's authorization number for that project;
2) The location of the research
			 project;
3) A general description
			 of the research or a copy of the research protocol;
4) A specific request to withhold the names
			 and/or any other identifying characteristics of the research subjects;
			 and
5) The reasons supporting the
			 request.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.10 - Authority

Current through Register Vol. 48, No. 28, July 12, 2024
This Part is promulgated pursuant to the Illinois Controlled
				Substances Act (the Act) [720 ILCS 570 ] which empowers
				the Department of Human Services to codify the efforts of this State to conform
				with the regulatory systems of the federal government and other states to
				establish national coordination of efforts to control the abuse of Schedule
				II-V dispensed drugs. It relates to the collection of prescription information
				listed in Schedule II-V within Sections 206, 208, 210, and 212 of the Act, or
				in the federal Schedule II-V and "Amendment of Schedules" list of drugs at
				21 USC
				812(b)(2), (b)(3), (b)(4), (b)(5) and
				(c).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.30 - General Description

Current through Register Vol. 48, No. 28, July 12, 2024
The ILPMP monitors all prescriptions for Schedule II-V drugs
				and drugs of interest (i.e., select drugs that are not included in Schedule II,
				III, IV or V) that are dispensed (except for hospital inpatients unless
				required by 720 ILCS 570/313) within the
				State of Illinois. Each time a Schedule II-V drug or drug of interest is
				dispensed, the dispenser must transmit specific information to a central
				repository within the ILPMP designated by the Department. The complete drug
				list is listed in the Illinois Data Submitter's Guide which is located at
https://rxsubmit-il.logicoy.com/PDMPSystemApp/guidebeforelogin#!#documents
.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.50 - Authorized Prescribers

Current through Register Vol. 48, No. 28, July 12, 2024
A prescription for a Schedule II-V drug shall be issued only by
				a prescriber who:
a) Possesses a valid
			 professional license issued by DFPR as a physician licensed to practice
			 medicine in all of its branches, dentist, optometrist, podiatrist,
			 veterinarian, advanced practice registered nurse granted full practice
			 authority, advanced practice registered nurse with delegated prescriptive
			 authority, a physician assistant with delegated prescriptive authority, or
			 other licensed prescriber of another state or jurisdiction;
b) Is licensed to prescribe Schedule II-V
			 drugs by the State of Illinois or any state;
c) Must be registered by the United States
			 Drug Enforcement Administration (DEA) to prescribe Schedule II-V drugs;
			 and
d) Complies with all
			 requirements under 21 CFR
			 1306.08 and
			 21 CFR
			 1311.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.70 - Schedule II-V Drug Prescription Requirements

Current through Register Vol. 48, No. 28, July 12, 2024
a) A dispenser may fill a prescription for a
			 Schedule II-V drug upon receipt of a written, electronic, facsimile, or verbal
			 order of a prescriber unless otherwise specifically exempted or allowed by
			 federal or State law.
b) A
			 prescription for a Schedule II-V drug shall:
1) Be dated as of and signed on the day when
			 issued;
2) Bear the full name and
			 address of the patient, or in the case of veterinary treatment, the full name
			 and address of the animal owner, as well as the species or common name of the
			 animal being treated;
3) Bear the
			 full name and address of the prescriber;
4) Bear the DEA Registration number of the
			 prescriber;
5) Have affixed to the
			 face of the prescription the prescriber's electronic or handwritten signature,
			 initials, thumbprint, or other biometric or electronic identification process
			 approved by DFPR pursuant to Section 3 of the Pharmacy Practice Act
			 [225 ILCS
			 85 ];
6)
			 If written, be written in ink with a pen, typewriter, or computer printer or
			 with an indelible pencil;
7)
			 Specify the drug name, strength, dosage, and form;
8) Specify the quantity of drug to be
			 dispensed, both written and numeric;
9) Not allow a Schedule II prescription to be
			 filled more than 90 days after the date of issue;
10) Not allow more than a 30-day supply of a
			 Schedule II drug on any one prescription;
11) Not allow for any refills of Schedule II
			 drugs;
12) Contain only one
			 Schedule II drug prescription order per prescription blank;
13) Limit the maximum time allowed for a
			 Schedule III, IV or V prescription to be filled at six months with a maximum of
			 five refills;
14) Allow more than
			 one prescription order per prescription blank for a Schedule III-V
			 drug;
15) Allow electronic
			 prescriptions in accordance with federal rules set forth in
			 21 CFR
			 1300,
			 1304,
			 1306,
			 1311
			 (2010) [720
			 ILCS 570/311.5 ]; and
16) Allow an individual
physician the
			 authority to prescribe multiple prescriptions (3 sequential 30-day supplies)
			 for the same Schedule II controlled substance, authorizing up to a 90-day
			 supply
[720 ILCS 570/312
			 (a-5)].
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.90 - Dispensing a Schedule II, III, IV or V Drug

Current through Register Vol. 48, No. 28, July 12, 2024
A prescriber who administers a Schedule II, III, IV or V drug
				in the course of the prescriber's professional practice subject to the Act may
				do so without issuing a written prescription for that drug.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.100 - Dispenser Responsibility

Current through Register Vol. 48, No. 28, July 12, 2024
a) Each
			 time a Schedule II-V drug or other selected drugs, as described in Section
			 2080.230, is dispensed, the
			 dispenser must transmit, by the end of the business day, to the central
			 repository the following data, and any other data deemed necessary by the
			 ILPMPAC:
1) Dispenser DEA number.
2) Dispenser's full name and
			 address.
3) Recipient's (or animal
			 and owner's) name and address.
4)
			 NDC identification number of the Schedule II-V drug dispensed.
5) Quantity of the Schedule II-V drug
			 dispensed.
6) Date prescription
			 filled.
7) Date prescription
			 written.
8) Prescriber DEA
			 number.
9) Prescriber full
			 name.
10) Patient ID.
11) Patient gender (M for male, F for female
			 or U for unknown).
12) Patient
			 birth date (yyyymmdd - year, month, day).
13) Date dispensed.
14) Payment type (i.e., Medicaid, cash,
			 third-party insurance).
15) Patient
			 location code (i.e., home, nursing home, outpatient, etc.).
16) Days' supply (based on dispensed
			 quantity).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.190 - Reports

Current through Register Vol. 48, No. 28, July 12, 2024
a) For the purpose
			 of intervention to prevent misuse, a prescriber or dispenser may request that
			 reports about their patients be sent to them via a secure method if a patient
			 meets the current PMP indications of potential misuse criteria set forth by the
			 PMPAC.
b) A personal information
			 report of a patient's prescription profile may be obtained if:
1) The patient, parent, or guardian completes
			 a notarized request; and
2) The
			 patient, parent, or guardian submits the notarized request by mail to the ILPMP
			 at:
Illinois Prescription Monitoring Program
401 North 4th Street, First
				Floor
Springfield, Illinois 62702
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.200 - Prescriber and Dispenser Inquiry System

Current through Register Vol. 48, No. 28, July 12, 2024
The Department's Bureau of Pharmacy and Clinical Support
				Systems or successor shall establish, operate, maintain, and enhance a
				stand-alone, one-to-one secure link with the necessary encrypted software that
				shall function as a prescriber and dispenser inquiry system to be known as the
				Illinois Prescription Monitoring Program (ILPMP). The Bureau must install a
				system to track each use of the ILPMP. The tracking system will only be
				utilized for the following purposes:
a)
			 Determining if a prescriber or dispenser is properly using the ILPMP. If it is
			 considered by the ILPMP staff that any registered user is not using the ILPMP
			 responsibly, an investigator from DFPR's Bureau of Drug Compliance will be
			 contacted in order to investigate the issue. If the ILPMP supervisor considers
			 the issue serious and of immediate concern, the registered user's ILPMP access
			 may be suspended.
b) Determining if
			 a non-registered person or entity is attempting to access the system. The ILPMP
			 staff shall report the situation to the Department and to one or more of the
			 following entities:
1) Illinois law
			 enforcement agency;
2) Illinois
			 regulatory entity;
3) federal
			 agency; or
4) an agency in another
			 state.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.205 - Accessing the ILPMP

Current through Register Vol. 48, No. 28, July 12, 2024
a) Prescribers
			 or dispensers or their authorized designee may utilize the ILPMP for patient
			 care after obtaining access authorization from the ILPMP staff.
b)
Each prescriber or their designee
			 shall also document an attempt to access patient information in the ILPMP to
			 assess patient access to controlled substances when providing an initial
			 prescription for Schedule II narcotics such as opioids, except for oncology
			 treatment, palliative care, or for a 7-day or less supply provided by a
			 hospital emergency department when treating an acute, traumatic medical
			 condition. This attempt to access shall be documented in the patient's medical
			 record.
[705 ILCS 570/314.5
			 (c-5)]
c) Only the following
			 licensed or non-licensed designee employed in that licensed prescriber's office
			 or a licensed designee in a licensed pharmacist's pharmacy who has received
			 training in the federal Health Insurance Portability and Accountability Act and
			 42 CFR
			 2 to consult the Illinois Prescription
			 Monitoring Program on their behalf [720 ILCS
			 570/316(g) ] shall serve as an
			 authorized designee for a prescriber or dispenser for entity or pharmacy
			 practice sites:
1) registered
			 nurse;
2) licensed practical
			 nurse;
3) pharmacy
			 technician;
4) student
			 pharmacist;
5) certified medical
			 assistant;
6) dental hygienist;
			 or
7) dental
			 assistant.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.207 - EHR Integration with the ILPMP

Current through Register Vol. 48, No. 28, July 12, 2024
a) EHR
			 systems are required to be integrated via PMP now through a one-to-one secure
			 link from the EHR to the ILPMP servers to allow information to return from the
			 ILPMP servers to the Requester directly.
1)
			 The connecting entity must maintain both an electronic and physical safeguard
			 of the information.
2) Security
			 failures or misuse will be handled as any other violation of the Health
			 Insurance Portability and Accountability Act (HIPAA) (42 USC
			 1320 et seq
.
).
3) A list of providers and locations served
			 by the EHR system must be provided to the ILPMP on a semi-annual basis,
			 supplied by the licensed healthcare entity or pharmacist in charge (this may
			 also be done at the corporate level of a healthcare or pharmacy organization)
			 and:
A) Shall contain the following
			 information:
i) Location name;
ii) Address;
iii) City;
iv) State;
v) Zip code;
vi) Contact at facility;
vii) Facility contact email
			 address;
viii) Health care provider
			 name (first and last);
ix) Health
			 care provider DEA;
x) Health care
			 provider NPI (National Provider Identifier); and
xi) Health care provider license
			 number.
B) Shall be sent
			 to the ILPMP in one of the following electronic formats:
i) Excel (.xlsx or .xls); or
ii) Comma separated values (.csv).
4) When requested, the
			 entity must provide an audit of the user that performed the search, the patient
			 information that was searched on, and the date and time of the
			 search.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.208 - Pharmacy Management Systems Integration with the ILPMP

Current through Register Vol. 48, No. 28, July 12, 2024
a) Pharmacy management systems are required
			 to be integrated via PMPnow through a one-to-one secure link connection from
			 the pharmacy management system to the ILPMP servers to allow information to
			 return from the ILPMP servers to the Requester directly.
1) The connecting entity shall maintain both
			 an electronic and physical safeguard of the information.
2) Security failures or misuse will be
			 handled as any other violation of the Health Insurance Portability and
			 Accountability Act (HIPAA) (42 U.S.C. 1320 et
			 seq
.
)
.
3) A list of pharmacists and pharmacy
			 locations using the pharmacy management system shall be provided to the ILPMP
			 on a semiannual basis and:
A) Shall contain
			 the following information:
i) Location
			 name;
ii) Address;
iii) City;
iv) State;
v) Zip code;
vi) Contact at pharmacy;
vii) Pharmacy contact email
			 address;
viii) Pharmacists' names
			 (first and last);
ix) Pharmacy DEA
			 number;
x) Pharmacy NPI;
			 and
xi) Pharmacists' license
			 numbers.
B) Shall be sent
			 to the ILPMP in one of the following electronic formats:
i) Excel (.xlsx or .xls); or
ii) Comma separated values (.csv).
4) When requested, the
			 connecting entity must provide an audit of the user that performed the search,
			 the patient information that was searched on, and the date and time of the
			 search.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.211 - Other State Prescription Monitoring Authority Access

Current through Register Vol. 48, No. 28, July 12, 2024
a) Other states may request access to the PMP
			 database:
1) After approval of a Memorandum of
			 Understanding from the Illinois Department of Human Services; and
2) After approval from the Department's
			 Bureau of Pharmacy and Clinical Support Systems' manager; the request must be:
A) related to a "probable cause"
			 investigation; or
B) for a health
			 care inquiry system for prescribers and dispensers.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.220 - Error Reporting

Current through Register Vol. 48, No. 28, July 12, 2024
a) If a
			 prescriber notices an error in their prescription information, they shall
			 report it to the dispensing pharmacy within 7 days after discovery of the
			 error.
b) A dispenser who notices
			 an error in a prescription they have dispensed and transmitted shall retract
			 the incorrect prescription and retransmit the prescription correctly within 7
			 days after discovery of the error.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.230 - Designated Controlled Substances and Other Selected Drugs

Current through Register Vol. 48, No. 28, July 12, 2024
For tracking purposes, the Department, upon recommendation of
				the PMPAC, may designate and list drugs, other substances, and immediate
				precursors as:
a) A Schedule I if the
			 Department finds that:
1)
the
			 substance has high potential for abuse; and
2)
the substance has no currently
			 accepted medical use in treatment in the United States or lacks accepted safety
			 for use in treatment under medical supervision
[720 ILCS
			 570/203 ].
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.240 - Mid-Level Practitioners Prescriptive Authority Reporting

Current through Register Vol. 48, No. 28, July 12, 2024
In order to prevent erroneous association of prescriptions and
				remain compliant with the PMP, any supervising or collaborating physician who
				has delegated prescriptive authority to a mid-level practitioner is required to
				log in and fill out the electronic form on the PMP website (www.ilpmp.org)
				detailing what prescriptive authority he or she has delegated in compliance
				with the Act. It is incumbent upon the collaborating or supervising physician
				to keep this record up to date. The form will require, but is not limited to,
				the following data fields:
a)
			 Mid-level practitioner's information necessary for the electronic PMP form:
1) Name (First, MI, Last);
2) DEA number;
3) Profession; and
4) Mid-Level Practitioner's Professional
			 License Numbers.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.245 - Advanced Practice Registered Nurse with Full Practice Authority

Current through Register Vol. 48, No. 28, July 12, 2024
a) An advanced
			 practice registered nurse granted Full Practice Authority under
			 225 ILCS
			 65/65-43 who prescribes Schedule II narcotic drugs,
			 such as opioids, shall establish a consulting relationship with a physician and
			 shall record that relationship in the ILPMP website (
www.ilpmp.org
). The advanced practice registered
			 nurse and the physician are both responsible for entering in the ILPMP the
			 name, DEA number, and license number of the consulting physician.
b) Information necessary for the ILPMP form:
1) Name (First, MI, Last);
2) DEA number;
3) Profession of the advanced practice
			 registered nurse; and
4)
			 Professional license numbers.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.250 - Mailing of Controlled Substances

Current through Register Vol. 48, No. 28, July 12, 2024
a)
Controlled substances may be
			 mailed if all of the following conditions are met
:
1)
The controlled substances are not
			 outwardly dangerous and are not likely, of their own force, to cause injury to
			 a person's life or health.
2)
The inner container of a parcel
			 containing controlled substances must be marked and sealed as required under
			 the Act and be placed in a plain outer container or securely wrapped in plain
			 paper.
3)
If the
			 controlled substance consists of prescription medicines, the inner container
			 must be labeled to show the name and address of the pharmacy or practitioner
			 dispensing the prescription.
4)
The outside wrapper or container
			 must be free of markings that would indicate the nature of the
			 contents.
[720 ILCS
			 570/312(k)(1) ]
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.320 - Illinois Prescription Monitoring Program Advisory Committee (ILPMPAC)

Current through Register Vol. 48, No. 28, July 12, 2024
The Illinois Prescription Monitoring Program Advisory Committee
				(ILPMPAC) is established to aid in the implementation of the ILPMP and to
				advise the Clinical Director on the professional performance of prescribers and
				dispensers and other matters relevant to the ILPMPAC's field of competence.
				[720 ILCS
				570/320(a) ]
a) The Clinical Director shall serve as a
			 non-voting secretary of the committee and appoint the members of the ILPMPAC
			 based on nominations from their respective professional associations. The
			 ILPMPAC
may appoint a chairperson and other officers as it deems
			 appropriate
. [720 ILCS
			 570/320(b) ]
b) Pursuant to
			 720 ILCS
			 570/320(b), the ILPMPAC shall consist
			 of the following:
1) one family or primary
			 care physician;
2) one pain
			 specialist physician;
3) four other
			 physicians licensed to practice medicine in all of its branches, one of whom
			 may be an ophthalmologist;
4) three
			 pharmacists;
5) two advanced
			 practice registered nurses;
6) one
			 dentist;
7) one
			 optometrist;
8) one clinical
			 representative from a statewide organization representing hospitals;
			 and
9) one physician
			 assistant.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2080 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM › Section 2080.325 - Peer Review Committee

Current through Register Vol. 48, No. 28, July 12, 2024
The ILPMPAC is authorized to have a standing subcommittee. This
				subcommittee shall be a ten-member Peer Review Committee. The Peer Review
				Committee shall advise the ILPMP on matters relating to the advisory
				committee's field of competence, establish a formal peer review of the
				professional performance of prescribers and dispensers, and develop
				communications to transmit to prescribers and dispensers. The deliberations,
				information, and communications of the Peer Review Committee are privileged and
				confidential and shall not be disclosed in any manner except in accordance with
				current law.
a) The ILPMPAC shall
			 select 10 of its members to be part of the Peer Review Committee.
b) The Peer Review Committee shall consist of
			 the following:
1) three physicians;
2) three pharmacists;
3) one dentist;
4) one advanced practice registered
			 nurse;
5) one physician assistant;
			 and
6) one optometrist.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.10 - Authority

Current through Register Vol. 48, No. 28, July 12, 2024
This Part is promulgated pursuant to the Illinois Controlled
				Substances Act that empowers the Department of Human Services to codify the
				efforts of this State to conform with the regulatory systems of the federal
				government and other states to establish national coordination of efforts to
				control the abuse of Schedule II, III, IV and V retail dispensed drugs. It
				relates to the collection of prescription information listed in Schedule II,
				III, IV and V within Sections 206, 208, 210 and 212 of the Act, or in the
				federal Schedule II, III, IV and V and "Amendment of Schedules" list of drugs
				at
				21 USC
				812(b)(2), (b)(3), (b)(4), (b)(5) and
				(c).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.30 - General Description

Current through Register Vol. 48, No. 28, July 12, 2024
The PMP monitors all controlled substances for Schedule II,
				III, IV and V drugs that are dispensed within the State of Illinois, except for
				those dispensed to hospital inpatients and by drug abuse treatment programs
				licensed by the Department. The LTC pharmacies transmit patient medication
				profiles to the PMP. Each time a Schedule II, III, IV or V drug is dispensed,
				the dispenser must transmit specific information to a central repository
				designated by the Department.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.40 - Long Term Care Pharmacies Responsibility

Current through Register Vol. 48, No. 28, July 12, 2024
LTC pharmacies shall transmit the patient medication profiles
				to the PMP weekly (see
				720 ILCS
				570/316(c)). The Department shall
				impose a civil fine of $100 per day for willful failure to comply with
				statutory reporting requirements. Assessment of the fine begins on the day
				after the report was required to be submitted and ends on the day the failure
				to report is remedied. Fines shall be payable to the Prescription Monitoring
				Program.
a) This information shall
			 include, but not be limited to, all the following data fields to provide the
			 clinical oversight required by Section 5-5.12(f) of the Public Aid Code or as
			 modified by DPH, HFS or DHS:
1) Dispenser DEA
			 number.
2) Name of the medication
			 as listed in Appendix A.
3)
			 Dispenser name and address.
4)
			 Patient information that should be kept up to date at all times:
A) Patient's name.
B) Patient ID.
C) Patient sex (M for male, F for female or U
			 for unknown).
D) Patient birth date
			 (yyyymmdd - year, month, day).
E)
			 Patient ethnicity (if available).
F) Patient location code (LTC facility State
			 provider number and corresponding location at the facility, i.e., unit and
			 room).
G) Pre-existing
			 conditions.
H) Patient weight, when
			 available electronically.
I)
			 Patient height, when available electronically.
5) For each prescription dispensed, the
			 following information must be included:
A) The
			 NDC identification number of the Schedule II, III, IV or V drugs or select
			 drugs.
B) Quantity of the drug
			 dispensed.
C) Dosing of the drug
			 dispensed.
D) Date when the drug
			 was dispensed.
E) Date prescription
			 was written.
F) Prescriber DEA
			 number.
G) Prescriber full
			 name.
H) Diagnosis.
I) Days' supply (based on dispensed
			 quantity).
6) For any
			 patient admissions to acute care facilities, the following information shall be
			 included:
A) Date admitted, if known to the
			 dispenser.
B) Date discharged, if
			 discharged at time of transmission, if known to the dispenser.
C) Reason for admission, if known to the
			 dispenser.
D) Any changes to
			 medication therapy involving medications in Appendix A, if known to the
			 dispenser.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.50 - Error Reporting

Current through Register Vol. 48, No. 28, July 12, 2024
a) If a
			 prescriber notices an error in his or her prescription information, that
			 prescriber shall report it to the Department by using the built-in PMP error
			 reporting system within 7 days after discovery of the error.
b) A dispenser who notices an error in a
			 prescription he or she has dispensed and transmitted shall retract the
			 incorrect prescription and retransmit the prescription correctly within 7 days
			 after discovery of the error.